

FDA Extends Enforcement Discretion Period for Regenerative Medicine Products, but This Isn't a Green Light for Bad Actors

August 6, 2020

ATTORNEYS

Landmon, Chad

Chad Landmon

Cell & Gene

PRACTICE AREAS

FDA

Axinn partner Chad Landmon co-authored the *Cell & Gene* article, "FDA Extends Enforcement Discretion Period for Regenerative Medicine Products, but This Isn't a Green Light for Bad Actors."

[Click here to access the article.](#)